|
|
|
|
187 * !
|
Tue, 8/10/2021,
1:30 PM -
3:20 PM
|
Virtual
|
|
Surrogate Markers and the Role of Mediation Analysis in Drug Development — Invited Papers
|
|
Biometrics Section, Lifetime Data Science Section, ENAR
|
|
Organizer(s): Peng Wei, The University of Texas MD Anderson Cancer Center
|
|
Chair(s): Peng Wei, The University of Texas MD Anderson Cancer Center
|
|
1:35 PM
|
Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level for Precision Oncology
Emily C Zabor, Cleveland Clinic
|
|
1:55 PM
|
Joint Modeling of Surrogate and Primary End Points via Causal Mediation Analyses
Yen-Tsung Huang, Academia Sinica
|
|
2:15 PM
|
A Survival Mediation Model with Bayesian Model Averaging
Jie Zhou, Cleveland Clinic Foundation; Peng Wei, The University of Texas MD Anderson Cancer Center; Brian Hobbs, The University of Texas at Austin
|
|
2:35 PM
|
Predicting Outcomes of Phase III Oncology Trials with Bayesian Mediation Modeling
Jie Zhou, Cleveland Clinic Foundation; Xun Jiang, Amgen; Amy Xia, Amgen; Peng Wei, The University of Texas MD Anderson Cancer Center; Brian Hobbs, The University of Texas at Austin
|
|
2:55 PM
|
Discussant: Stijn Vansteelandt, Ghent University
|
|
3:15 PM
|
Floor Discussion
|
